toxylact: a06AH methylnatrexon bromide

The first professional lActological database in the word

Methylnaltrexone bromide (A06AH01) is a peripherally acting opioid receptor antagonist used for opioid‑induced constipation and is generally not recommended during breastfeeding due to limited human data and potential risk of opioid withdrawal in the infant.mayoclinic+4

Pharmacotherapeutic group and mechanism

Methylnaltrexone bromide is classified as a laxative within the ATC subgroup A06AH “Peripheral opioid receptor antagonists,” with code A06AH01.atcddd.fhi+2
It selectively antagonizes µ‑opioid receptors in the gastrointestinal tract, reversing opioid‑induced inhibition of gut motility and secretion without significant impact on central analgesia because its quaternary ammonium structure restricts blood–brain barrier penetration.medsafe+1

Indications, dosage and administration

Methylnaltrexone is indicated for the treatment of opioid‑induced constipation (OIC) in adult patients with chronic non‑cancer pain and in patients receiving palliative care when conventional laxatives have been insufficient.dailymed.nlm.nih+3
The WHO ATC/DDD Index assigns a defined daily dose of 6 mg parenteral (P) for A06AH01, reflecting typical subcutaneous dosing in clinical practice.atcddd.fhi
Product information describes subcutaneous doses of 8–12 mg every 48 hours in advanced illness and 12 mg once daily or at least four times weekly in chronic non‑cancer pain; oral tablets (450 mg once daily) are also approved for chronic OIC.mayoclinic+3

General toxicological profile

Class‑related adverse reactions are mostly gastrointestinal, including abdominal pain, cramping, diarrhea, nausea, flatulence and, less frequently, vomiting.medicines+3
By reversing peripheral opioid effects, methylnaltrexone can precipitate symptoms consistent with opioid withdrawal (e.g. hyperhidrosis, chills, anxiety, yawning) in some patients, particularly those receiving high‑dose opioids.dailymed.nlm.nih+2
Serious gastrointestinal events such as perforation have been reported in patients with conditions that predispose to reduced structural integrity of the gut wall, and product information includes warnings for patients with known or suspected intestinal obstruction or malignancy‑related lesions.medsafe+3
Preclinical reproductive studies and clinical experience do not indicate major teratogenicity, but data in pregnancy are limited and caution is advised; standard contraindications include hypersensitivity to methylnaltrexone or excipients.medsafe+2

Lactation‑toxicology considerations

Regulatory documents state that it is not known whether methylnaltrexone bromide is excreted in human breast milk and recommend that women using this medicine should not breast‑feed during therapy.mayoclinic+2
Animal studies with radiolabeled methylnaltrexone demonstrate excretion into milk of lactating rats, indicating a potential for transfer into breast milk in mammals.accessdata.fda
Product‑level warnings emphasize that taking methylnaltrexone while breastfeeding may cause opioid withdrawal in the baby, leading manufacturers to advise against breastfeeding during treatment and for a period after the last dose.mayoclinic+2

From a mechanistic standpoint, methylnaltrexone’s polarity and poor oral bioavailability suggest that amounts ingested by the infant via milk might be limited and incompletely absorbed, but definitive pharmacokinetic data in breastfed infants are lacking. Any absorbed drug could antagonize opioid receptors in the infant gut or systemically, theoretically interfering with analgesia if the infant receives opioids or precipitating withdrawal symptoms when maternal opioids cross into breast milk. Major lactation references therefore classify methylnaltrexone as lacking sufficient evidence for safe routine use in breastfeeding, favoring avoidance when alternatives for constipation are available.e-lactancia+1

Clinical use in breastfeeding women

In breastfeeding women with opioid‑induced constipation, non‑pharmacological measures (hydration, diet, physical activity) and conventional laxatives with established lactation safety profiles (e.g. osmotic or bulk‑forming agents) are preferred. When methylnaltrexone is considered clinically necessary—such as refractory OIC in a postpartum woman on high‑dose opioids—an individualized risk–benefit assessment is essential, and specialist consultation in clinical pharmacology or lactation medicine is recommended.e-lactancia+2
If no suitable alternative exists and therapy is initiated, current labeling supports either temporary interruption of breastfeeding or using methylnaltrexone only while carefully monitoring the infant for feeding difficulties, changes in stool pattern, irritability or signs of opioid withdrawal (e.g. high‑pitched cry, tremor, sweating).mayoclinic+3

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.